Lupin Limited · NSE:LUPIN
Lupin — Q3 FY24 Earnings Presentation
23 slides from Lupin's earnings presentation, Feb 8, 2024
Slide 1: Exchange filing cover letter
February 8, 2024 BSE Limited Department of Corporate Services, P. J. Towers, Dalai Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation Q3 FY24. Pursuant to Regulation 30(
Slide 2: Investor Presentation Q3 FY24
Investor Presentation Q3 FY24 February 08, 2024
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q3 FY24 Performance
er LUPIN Q3 FY24 Performance
Slide 5: Q3 FY24: Key Growth Metrics
Q3 FY24: Key Growth Metrics Strong execution on all fronts Key Metrics Business Performance INR mn India North America 50,799 mn 17,251 mn 18,885 mn Sales 13% YoY 24% YoY 20% YoY EMEA 10,220 mn 20.1% Growth Markets EBITDA1 Margin 4,729 mn 5,170 mn 13% YoY 36% YoY 98% YoY API ROW 6,131 mn 12.1% 2,779
Slide 6: Q3 FY24: Key Developments
Q3 FY24: Key Developments Consistent trajectory of improved profitability Financials Complex Generics gProlensa Sales and Adj. EBITDA* Trajectory gSpiriva Gaining Launched in Ophthalmic 60,000 30.0% DPI momentum US 50,799 Solution 50,000 45,369 49,392 25.0% 42,446 43,303 Business Development 40,000
Slide 7: Q3 FY24 Financial Snapshot
Q3 FY24 Financial Snapshot Sales Mix Key Financials INR in mn Revenue (In INR mn and %) North Q3 FY24 Q3 FY23 Q2 FY24 India, America, 17,251 , 18,885 , 34% 37% Sales 50,799 42,446 49,392 API, 2,779 , EBITDA* 10,220 5,160 9,231 Growth 6% Markets, ROW, 1,985 , EMEA, 4,729, 5,170 , 9% Net Income 6,131
Slide 8: India: Outperforming market growth
India: Outperforming market growth India Rx business grew 12.9% in Q3FY24 (1.6x IPM Leveraging therapy leadership; Added 7 growth) new divisions in last 12 months India Sales (INR mn) 16,384 16,915 17,251 #2 rank #3 rank #3 rank 15,213 14,786 Respiratory Diabetes Care Cardiac • Chronic share ~62% of
Slide 9: India: Amplifying our Core
India: Amplifying our Core Lupin prescription business is positioned to outperform Enabling end to end healthcare ecosystem and access IPM with key drivers in place for the patient Enhancing penetration and reach • Maximizing Chronic therapy focus CHC Portfolio catering to GI, Business Verticals • S
Slide 10: North America: Delivering on Complex Generics
North America: Delivering on Complex Generics Leadership: 4.3% TRx Consistent ramp up in sales Growing Respiratory volume share in U.S.1 portfolio US Sales ($mn) 177 175 181 213 212 #3 #1 22.5% 28.6% in the US1 in 50 products2 Albuterol Arfomoterol Q3 Q4 Q1 Q2 Q3 market share market share Maintainin
Slide 11: Other Markets: Key Highlights
Other Markets: Key Highlights Consistent performance in developed markets Emerging Markets • Steady growth registered in key markets • BRL 54 mn sales in Q3 FY24 EU • Growth driven by higher Brazil • Rank 2nd in reference market3 Luforbec® and tender sales • Revenues up 150% QoQ (local • 7th largest
Slide 12: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and Achieve Best-in-Class Quality biosimilars Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end to end capabilities Successful outcomes in last 9 months of MDIs, DPIs, Soft-Mist In
Slide 13: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) Capex (INR mn) Net debt/ Equity 15.0% 3,900 3,679 3,764 3,567 2,000 15.0% 1,848 13.0% 3,600 0.27 13.0% 1,555 1,502 11.0% 3,300 2,896 3,050 1,345 3,000 1,500 11.0% 9.0% 0.20 2,700 1,171 2,400 9.0% 7.0% 2,100 1,000 0.14 1,800 7.0% 5.0% 7.8% 7.6% 7.0%
Slide 14: P&L Highlights Q3 FY24
P&L Highlights Q3 FY24 % of % of YoY % of QoQ Amount in INR mn Q3FY24 Q3FY23 Q2FY24 Sales Sales Growth Sales Growth Sales 50,799 100.0% 42,446 100.0% 19.7% 49,392 100.0% 2.8% Other operating income 1,175 2.3% 776 1.8% 51.4% 994 2.0% 18.2% Total revenue 51,974 102.3% 43,222 101.8% 20.2% 50,386 102.0%
Slide 15: P&L Highlights 9M FY24
P&L Highlights 9M FY24 YoY Amount in INR mn 9MFY24 % of Sales 9MFY23 % of Sales Growth Sales 147,612 100.0% 119,397 100.0% 23.6% Other operating income 2,888 2.0% 2,719 2.3% 6.2% Total revenue 150,500 102.0% 122,116 102.3% 23.2% Gross Profit 96,916 65.7% 69,101 57.9% 40.3% (excl. other operating inc
Slide 16: Lupin at a Glance
Lupin at a Glance
Slide 17: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY23 Sales) 13th Largest in 7th India Pharma Largest Generic 3 rd the US Market Rank 37% INDIA 8% Developed Company (by prescriptions3) Markets (by sales3) (by sales1) 32% Largest Largest US $2
Slide 18: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale as effic
Slide 19: Lupin's ESG Journey in 2023
Lupin’s ESG Journey in 2023 Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Risk Management Lupin has enhanced the scope, nature and boundary of disclosures and multiple actions delivered at ground level in 2023 Continuous Efforts for Enhancements in t
Slide 20: ESG: Ratings update in 2023
ESG: Ratings update in 2023 Committed to accountability and public disclosure of ESG initiatives and metrics Lupin has made progress in ratings in 2023 responses in both S&P Global CSA and featured as a Yearbook Member 2024 and also scored B in CDP Climate and C in Water Agency 2021 2022 2023 Trends
Slide 21: ESG: Way forward in 2024
ESG: Way forward in 2024 Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Risk Management For 2024, Lupin will focus on the below key actions to create a meaningful impact among others Environment Social Governance Establish a comprehensive GHG Emission
Slide 22: Lupin – Awards and Accolades
Lupin – Awards and Accolades Organizational Awards Leadership and Other Awards • ATD (Association of Talent • Vinita Gupta, named among India’s 20 Most Influential Development) BEST Award Women in Healthcare by 2022 BW Healthcare World • ‘Factories of the Future’ at the Economic Times Promising Plan
Slide 23: Thank You
youtube.com/c/LupinGlobal twitter.com/LupinGlobal linkedIn.com/company/lupin facebook.com/LupinWorld/ Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 | www.lupin.com